- Home
- AMGN
AMGN
Amgen Inc.
as 11-18-2024 4:00pm EST
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 152.1B | IPO Year: | N/A |
| Target Price: | $334.58 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.83 | EPS Growth: | -44.29 |
| 52 Week Low/High: | $260.52 - $346.85 | Next Earning Date: | 10-30-2024 |
| Revenue: | $32,534,000,000 | Revenue Growth: | 21.25% |
| Revenue Growth (this year): | 20.06% | Revenue Growth (next year): | 3.50% |
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now?
Zacks
a day ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Morningstar Research
a day ago
Analyst Report: Amgen Inc.
Yahoo Finance
3 days ago
The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?
Motley Fool
3 days ago
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
Simply Wall St.
3 days ago
The three-year decline in earnings for Amgen NASDAQ:AMGN) isn't encouraging, but shareholders are still up 50% over that period
PR Newswire
5 days ago
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
Zacks
5 days ago
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Compare AMGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.